How to Validate Your Idea Rigorously
Interview with Flow Medical CEO Jennifer Fried
Key Learnings From Jennifer's Experience
For future M&As: engage early, plan intentionally, and nurture relationships. A proactive approach will help you gain an understanding of the market as well as get to know your potential acquirers and their interests. Having these conversations early, when there’s no M&A deal on the table, is much easier. And when there is, you’ll know the ropes by then.
Be intentional about challenging your assumptions, conduct unbiased customer discovery, and lean on data and patterns rather than personal biases. This upfront effort helps you ensure the problem is real, meaningful, and worth solving. It will also save you from unnecessary time and resource investment.
Build meaningful, lasting relationships by personalizing your approach, understanding your audience, and staying persistent. Leverage your network to create warm connections, tailor your pitch to your audience, and use rejection as an opportunity to foster future relationships. Raising capital requires preparation, adaptability, and consistent follow-up to keep potential investors engaged over time.
Jennifer Fried returns to Medsider, now with an exit under her belt. The last time we spoke to her in 2020, she was leading ExplORer Surgical, a medtech company that provides a digital platform that offers real-time surgical support to enhance operating room efficiency and outcomes. Since then, ExplORer, which she co-founded, has been acquired by Global Healthcare Exchange (GHX). Today, Jennifer is embracing new challenges as the co-founder and CEO of Flow Medical, a company developing next-generation pulmonary embolism thrombolysis catheters.
Here’s a recap on Jennifer’s background: After starting at Bain & Company, she transitioned into healthcare venture capital, where she gained exposure to late-stage medical devices and healthcare software. Her entrepreneurial chapter began with a University of Chicago spin-out in 2016, ExplORer Surgical. Now, she’s channeling her expertise into Flow Medical, a venture born from a collaboration between two physicians at the University of Chicago, Drs. Jonathan Paul and Osman Ahmed, who identified the limitations of existing tools during the COVID-19 pandemic. They designed the concept for the catheter in December 2020 and worked with the Polsky Center, NIH programs, and engineering partners to bring it to life.
Pulmonary embolism is a condition where blood clots block arteries in the lungs. Flow’s device is inserted through a vein in the leg and guided to the lungs. Once in place, it expands to make direct contact with the clot, delivering a medication called a tissue plasminogen activator (TPA) that dissolves the blockage. The catheter also monitors blood pressure in real-time, helping doctors determine the optimal amount and duration of medication needed.
Flow Medical is approaching key milestones, including a design freeze and preparations for human trials, with an anticipated IDE submission by late 2025.
Guest
Co-founder and CEO of Flow Medical
Jennifer Fried started her career as a healthcare venture capitalist and consultant at Bain & Company. Before co-founding Flow Medical, Jennifer was the CEO and co-founder of ExplORer Surgical, a surgical software platform spun out of research at The University of Chicago. Under her leadership, ExplORer grew from an idea to a global product, earning accolades, like being named one of the Top 50 Healthcare Technology CEOs, and partnerships with major medical device companies. Jennifer successfully exited the business in 2021, when it was acquired by GHX.
Sponsor Message
We recently released the seventh volume of Medsider Mentors, which summarizes key learnings from the most popular Medsider interviews over the last six months.
We get it—keeping up with every Medsider interview isn’t easy. That’s why we created Medsider Mentors. These e-book volumes distill the best practices and insider secrets from top founders and CEOs, all in a downloadable, easy-to-digest format.
Check out the latest volume here. Premium members get free access to all past and future volumes, plus a treasure trove of other resources.
If you’re not a premium member yet, you should definitely consider signing up. We recently revamped Medsider with swanky new features, especially for our premium members. In addition to every volume of Medsider Mentors, you’ll get full access to our entire interview library, dating back to 2010.
You’ll also get Medsider Playbooks—curated guides packed with actionable insights on topics like fundraising, regulatory challenges, reimbursement strategies, and more.
And if you’re fundraising, don’t miss our exclusive investor database, featuring over 750 life science VCs, family offices, and angels. We’ve even created 3 custom packages to help you with your next fundraise.
Learn more by visiting Medsider Mentors.
How Startups Should Engage with Strategics
Jennifer’s approach to M&A boils down to one key strategy: start early and stay engaged.
Before joining Flow, she reached out to the companies she saw as potential acquirers to say, “Hey, let’s have this conversation now. Because when I call you next time, I’ll likely be at Flow, and it’s going to be a different conversation.”
The point of such early engagement isn’t to rush toward an exit, but to build relationships and understand the market. It’s a huge asset to be able to plant seeds early and establish credibility long before any formal M&A discussions begin.
During those types of conversations, Jennifer also likes to raise some critical questions, such as: “What do you see happening in this space?” and “What trends or innovations are driving inflection points?” These are important to get a clear vision of what may lie ahead.
It’s worth noting that not everyone will have the ability to make those kinds of direct calls right away. Jennifer’s approach reflects her experience and the network she’s built over the years. If you’re just starting out, you might not have a ready-made contact list or the credibility to start those conversations immediately—but that doesn’t mean you can’t build toward it.
Jennifer also draws on advice from Mert Iseri’s book, Exit Right, recommending that entrepreneurs adopt an annual process of evaluating their potential acquirers. She advises, “Once a year, sit down and say, ‘Who are my top five or ten acquirers? Have I talked to them this year? Do I know what they’re doing? Do they know who I am?’” This structured approach keeps the conversation alive without overwhelming day-to-day operations.
For Jennifer, this isn’t just networking; it’s creating a trend line. “You’re planting these different seeds and showing them progression over time. First, here’s the idea. Then, here’s our device. Next year, here’s our first patient. It’s all about building trust and demonstrating momentum,” she notes.
Her advice for entrepreneurs who prefer to stay hidden is, simply don’t. She believes the real opportunity lies in transparency and openness. “If and when the time is right, you want those relationships in place. You want them to see your journey and know your story,” she shares.
How to Assess the Validity of an Idea
When Jennifer was considering taking on her role at Flow Medical, she didn't jump in headfirst. Instead, she dedicated six months to challenge the concept.
“I kept looking for somebody to give me a reason to say ‘no’ because having gone through this journey, I know how hard it is and didn’t want to set myself up for a long, painful ride.” This isn’t to say you should be a skeptic. You just need to do your due diligence. Startups demand time, capital, and resilience, so validating an idea upfront is crucial—it might save you years of effort. “You’re betting your most important asset—your time—on this idea. You need to be sure it’s worth it,” she says.
It also takes setting aside personal biases. “As a subject matter expert, it’s easy to think, ‘I have this problem, so everyone must have this problem,’ But the reality is, you have to validate it. The problem might not be as universal or meaningful as it feels to you,” she explains.
She emphasizes the importance of true customer discovery, which she sees as often overlooked. Before she co-founded Flow, she called dozens of, interventional cardiologists and radiologists. She started by asking open-ended questions. Rather than pitching her idea, she focused on understanding the broader context. She asked questions like, “How many cases do you see in a year?” “What are your biggest challenges in this area?” or “What tools are you using and why would you pick one tool over the other?” This way, she could explore decision-making processes and gaps in the field without leading her audience toward specific answers
She also leaned on volume to uncover patterns. “You need to find a dozen, two dozen, or even three dozen other experts,” she says. It’s only after speaking to enough people that recurring themes emerge, pointing to problems worth solving.
While doing your market research, or customer discovery, it’s also important to be consistent. Jennifer made sure to ask the same set of questions, in the same order, every time. “And they need to be non-leading,” she emphasizes. This structure prevents steering the conversation and ensures feedback is authentic.
Many entrepreneurs are tempted to skip this foundational work and dive straight into product development. Jennifer cautions against this. “You can save yourself a lot of time and headaches by doing this work upfront,” she says. After six months of discovery and analysis, which also included conversations with her VC friends and various cardiovascular companies, Jennifer had her answer. Challenging her assumptions and digging deep gave her the clarity and confidence to move forward. “I realized this is the most compelling opportunity in medtech I’ve ever seen. I’d be insane not to do it.”
Building Connections That Last
Jennifer brings her network to the game of raising capital. “We live in a very connected world,” she says. “The world gets smaller every day”. For her, the key is to create warm connections. “People respond to people more than they respond to companies,” Jennifer adds.
This begins with maximizing your network. Whether it’s reaching out to friends, colleagues, or alumni groups, Jennifer advises entrepreneurs to seek common ground. She often responds to outreach from Northwestern or University of Chicago students who reference their shared affiliation. These small, personalized touches can open doors to meaningful conversations
Preparation is equally critical. Jennifer stresses the importance of understanding your audience before the pitch. “Go into the meeting knowing who you’re talking to,” Jennifer advises. She sends her pitch deck and a one-minute explainer video in advance to give potential investors context. During the meeting, she tailors her approach based on the audience’s familiarity with her space. “How I present Flow to interventionalists is completely different from how I present to a generalist medtech VC,” she says.
Jennifer also does a lot of investment in healthcare, specifically women’s health. She knows the importance of giving investors a reason to engage, especially for entrepreneurs without existing connections. “If it’s an entrepreneur who doesn’t know me, they need to give me a reason to take the call,” she shares. This could mean showing they’ve done their homework—whether by referencing her investment focus or connecting on mutual interests. For example, she’s more likely to engage with someone who acknowledges her track record in women’s healthcare and demonstrates how their pitch aligns with her expertise. Conversely, generic or sloppy outreach—like misspelling her name—will go unanswered.
The takeaway is that you should reshape the conversation based on the investor’s perspective. For that, you need to understand their position. Start with curiosity about the investor’s perspective. You can ask questions like, “What’s your familiarity with this space?”, “Have you looked at similar companies before?, “Does this fit with your fund’s thesis or mandate?” Jennifer also emphasizes that it’s important to leave time to ask these questions and close the loop at the end of the meeting. “It’s uncomfortable at first, but good hygiene for managing relationships,” she points out.
Jennifer is pragmatic about rejection. Not every investor will say yes—and that’s okay. “A ‘no’ is rarely a no forever,” she reminds. Instead, it’s an opportunity to build a relationship for the future. Even when an investor isn’t ready to commit, periodic updates can keep them engaged and position you for future conversations. “If someone says they’re not interested right now, great—then I’ll email them in six months with an update.”
Jennifer is upfront about the effort involved in raising capital. “It’s time-intensive, but your ability to connect and pitch effectively is critical,” she says, and adds, “The more you practice this, the easier it becomes.”
Sponsor Message
After raising over $40M from corporate venture and cardiovascular key opinion leaders, FastWave Medical has progressed rapidly in the development of its next-generation intravascular lithotripsy (IVL) systems for complex calcific disease.
The market size for IVL is over $9 billion and the only player in the space was recently acquired for over $13 billion. So naturally, there’s a lot of investor interest in FastWave.
Given the continued demand to invest in FastWave, their team has opened up an investor waitlist for anyone interested in potentially owning a piece of the company.
The last time the company opened up an private placement, it closed nearly $20 million in less than a month. So if you’re interested in investing in one of the hottest cardiovascular startups, opt into their investor waitlist here.
You May Like These Articles
Medsider Premium
Become a premium member and unlock access to exclusive Medsider benefits.